The interplay of metabolic dysfunction-associated fatty liver disease and viral hepatitis on liver disease severity: A large community-based study in a viral endemic area.
暂无分享,去创建一个
Ming‐Lung Yu | M. Yeh | Chung‐Feng Huang | C. Dai | Po-Cheng Liang | W. Chuang | M. Hsieh | Pei-Chien Tsai | Chih-Wen Wang | Tyng-Yuan Jang | Po-Yao Hsu | Yu-Ju Wei | Yi‐Hung Lin | Ching-I Huang | Jee‐Fu Huang
[1] Ming‐Lung Yu,et al. Community-centered Disease Severity Assessment of Metabolic Dysfunction-associated Fatty Liver Disease , 2023, Journal of clinical and translational hepatology.
[2] Ming‐Lung Yu,et al. A people-centered decentralized outreach model toward HCV micro-elimination in hyperendemic areas: COMPACT study in SARS Co–V2 pandemic , 2023, Journal of Microbiology, Immunology and Infection.
[3] S. Ohnishi,et al. Hepatitis C virus eradication by direct‐acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low‐density lipoprotein cholesterolemia without an increase in body weight , 2023, Hepatology research : the official journal of the Japan Society of Hepatology.
[4] V. de Lédinghen,et al. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study) , 2023, Hepatology.
[5] C. Liu,et al. Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives , 2023, Clinical and molecular hepatology.
[6] S. Ahn. Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments , 2023, Clinical and molecular hepatology.
[7] J. Yu,et al. Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future , 2022, Clinical and molecular hepatology.
[8] L. Castéra,et al. Identification of high-risk subjects in nonalcoholic fatty liver disease , 2022, Clinical and molecular hepatology.
[9] C. Byrne,et al. Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future , 2022, Clinical and molecular hepatology.
[10] I. Waked,et al. Prevalence and clinical characteristics of patients with metabolic dysfunction‐associated fatty liver disease with hepatitis C virus infection—a population‐based study , 2022, Alimentary pharmacology & therapeutics.
[11] M. Yuen,et al. Steatosis, HBV‐related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta‐analysis , 2022, Hepatology.
[12] Ming‐Lung Yu,et al. Amelioration of glucose intolerance through directly acting antiviral agents in chronic hepatitis C cirrhotic patients without overt diabetes , 2022, The Kaohsiung journal of medical sciences.
[13] M. Vacca,et al. Metabolic dysfunction and cancer in HCV: shared pathways and mutual interactions. , 2022, Journal of hepatology.
[14] M. Yuen,et al. On‐treatment gamma‐glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients , 2021, Liver international : official journal of the International Association for the Study of the Liver.
[15] Ming‐Lung Yu,et al. The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments , 2021, Biomedicines.
[16] V. Wong,et al. Incidences and Determinants of Functional Cure during Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. , 2021, The Journal of infectious diseases.
[17] J. Lazarus,et al. MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective , 2021, Alimentary pharmacology & therapeutics.
[18] Ming‐Lung Yu,et al. Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan , 2021, BMJ Open.
[19] Shigui Yang,et al. Concurrence and impact of hepatic steatosis on chronic hepatitis B patients: a systematic review and meta-analysis , 2021, Annals of translational medicine.
[20] Hwai I. Yang,et al. Association between fatty liver and cirrhosis, hepatocellular carcinoma, and HBsAg seroclearance in chronic hepatitis B. , 2020, The Journal of infectious diseases.
[21] P. Lampertico,et al. Hepatic Fat—Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs , 2020, Hepatology.
[22] W. Lai,et al. Cure or curd: Modification of lipid profiles and cardio‐cerebrovascular events after hepatitis C virus eradication , 2020, The Kaohsiung journal of medical sciences.
[23] S. Friedman,et al. Prevalence and Profile of Nonalcoholic Fatty Liver Disease in Lean Adults: Systematic Review and Meta‐Analysis , 2020, Hepatology communications.
[24] V. Wong,et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. , 2020, Journal of hepatology.
[25] G. Marchesini,et al. Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation , 2020, Hepatology.
[26] M. Manns,et al. Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C—Results from the German Hepatitis C-Registry (DHC-R) , 2019, Zeitschrift für Gastroenterologie.
[27] R. Hultcrantz,et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long‐term follow‐up study , 2017, Hepatology communications.
[28] Ming‐Lung Yu,et al. The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon‐free direct antiviral agents , 2017, The Kaohsiung journal of medical sciences.
[29] D. Consonni,et al. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[30] G. Papatheodoridis,et al. Non-alcoholic fatty liver disease may develop in individuals with normal body mass index , 2012, Annals of gastroenterology.
[31] H. Cortez‐Pinto,et al. Hepatic steatosis in hepatitis B virus infected patients: Meta‐analysis of risk factors and comparison with hepatitis C infected patients , 2011, Journal of gastroenterology and hepatology.
[32] V. de Lédinghen,et al. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. , 2010, Ultrasound in medicine & biology.
[33] Yoshiyuki Suzuki,et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C , 2009, Hepatology.
[34] T. Asselah,et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. , 2006, Gastroenterology.
[35] Erick M Remer,et al. The utility of radiological imaging in nonalcoholic fatty liver disease. , 2002, Gastroenterology.